产品名称	LC-1/sq人肺癌鳞癌细胞
货号	ZQ1149
产品介绍	LC-1/sq人肺癌鳞癌细胞是一种从人类肺癌组织中分离出来的细胞系，在癌症研究中非常有用，因为它们可以模拟肺癌的某些特性，帮助科学家研究癌症的生物学行为、药物筛选和治疗方法的开发。
种属	人
性别/年龄	男/69岁
组织	肺癌
疾病	肺癌，鳞癌
细胞类型	肿瘤细胞
形态学	上皮
生长方式	贴壁
倍增时间	大约64.6 hours (PubMed=1917142); ~75 hours (Note=Lot 11122004) (JCRB=JCRB0258)
培养基和添加剂	RPMI-1640/F-12(1:1)（品牌：中乔新舟 货号：ZQ-200 货号：ZQ-400）+10%胎牛血清（中乔新舟  货号：ZQ500-A）+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM1149
生物安全等级	BSL-1
培养条件	95%空气，5%二氧化碳；37℃
STR位点信息	Amelogenin： X CSF1PO ：12 D5S818： 12,13 D7S820 ：12 D13S317： 12,13 D16S539： 9 TH01 ：7,9 TPOX ：8,12 vWA： 17,18
抗原表达/受体表达	***
基因表达	***
保藏机构	JCRB; JCRB0258  RCB; RCB0455
供应限制	仅供科研使用

PubMed=1917142; DOI=10.1002/ijc.2910490322
Itoh H., Kataoka H., Koita H., Nabeshima K., Inoue T., Kangawa K., Koono M.
Establishment of a new human cancer cell line secreting protease nexin-II/amyloid beta protein precursor derived from squamous-cell carcinoma of lung.
Int. J. Cancer 49:436-443(1991)

PubMed=8348978; DOI=10.1016/0014-5793(93)80946-R
Kataoka H., Seguchi K., Inoue T., Koono M.
Properties of alpha 1-antitrypsin secreted by human adenocarcinoma cell lines.
FEBS Lett. 328:291-295(1993)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9538136; DOI=10.3892/ijo.12.5.1103
Takaki T., Hiraki A., Uenaka A., Gomi S., Itoh K., Udono H., Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.
Variable expression on lung cancer cell lines of HLA-A2-binding MAGE- 3 peptide recognized by cytotoxic T lymphocytes.
Int. J. Oncol. 12:1103-1109(1998)

PubMed=10536175; DOI=10.3892/ijo.15.5.927
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Int. J. Oncol. 15:927-934(1999)

PubMed=11005564; DOI=10.1038/sj.neo.7900094
Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.
Mutation and expression of the DCC gene in human lung cancer.
Neoplasia 2:300-305(2000)

PubMed=14581340
Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Clin. Cancer Res. 9:4705-4713(2003)

PubMed=15185009; DOI=10.1007/s00262-004-0533-9
Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H., Motohashi S., Yokoi S., Hiroshima K., Tagawa M., Nakayama T., Fujisawa T.
Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.
Cancer Immunol. Immunother. 53:786-792(2004)

PubMed=15746151; DOI=10.1093/hmg/ddi092
Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I.
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Hum. Mol. Genet. 14:997-1007(2005)

PubMed=19472407; DOI=10.1002/humu.21028
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)

PubMed=24002593; DOI=10.1038/bjc.2013.452
Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.
Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.
Br. J. Cancer 109:1599-1608(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)